“Following the interim results of phase I clinical trials, the Pasteur Institute is suspending the development of one of its candidate vaccines based on the measles virus vaccine,” the BFMTV Institute said.
As clarified by France Bleu, clinical trials were conducted in August 2020 and showed a lower immune response in subjects compared to already approved vaccines, as well as the immune response that is observed in those who recovered from coronavirus.
At the same time, the Pasteur Institute intends to continue developing its other vaccine candidates, which have passed the preclinical phase of trials.
Earlier it was reported that 1 million people were vaccinated against coronavirus infection in France.
At the end of December, France allowed the use of the COVID-19 vaccine by the American pharmaceutical corporation Pfizer and the German company BioNTech.